SCHEMBL31146205

SCHEMBL31146205

Cc1c(C(C)C(=O)N[C@@H](C)c2ccc(F)cc2F)c(=O)[nH]c2ccncc12

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.41
▸ GPR139 Q6DWJ6 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPK1 P28482 1/20 0.36
▸ KDM5A P29375 1/20 0.36
▸ PDE2A O00408 4/20 0.36
▸ CHUK O15111 1/20 0.36
▸ PADI4 Q9UM07 1/20 0.35
▸ ROCK2 O75116 3/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ PARP1 P09874 2/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146120 0.89 ACHE (0.38) ACHEGPR139KMT2AHSD17B10MAPK1
SCHEMBL31146146 0.89 ACHE (0.38) ACHEGPR139KMT2AHSD17B10MAPK1
SCHEMBL31146016 0.83 MAPK1 (0.38) GPR139KMT2AHSD17B10MAPK1PDE2A
SCHEMBL31146176 0.83 MAPK1 (0.38) GPR139KMT2AHSD17B10MAPK1PDE2A
SCHEMBL31145880 0.83 MAPK1 (0.38) GPR139KMT2AHSD17B10MAPK1PDE2A
SCHEMBL31146123 0.78 PDE2A (0.39) GPR139PDE2APADI4PARP1
SCHEMBL31145919 0.78 GPR139 (0.44) ACHEGPR139KMT2AHSD17B10MAPK1
SCHEMBL31146230 0.76 PDE2A (0.39) GPR139KMT2AHSD17B10MAPK1PDE2A
SCHEMBL31145968 0.74 PARP1 (0.47) ACHEKDM5APARP1CSNK2A1
SCHEMBL31145938 0.73 KDM5A (0.44) ACHEKMT2AKDM5AROCK2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A ACHE 655/4885GPR139 4135/4885KMT2A 2432/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A ACHE 655/4885GPR139 4135/4885KMT2A 2432/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 ACHE 1756/4885GPR139 4225/4885KMT2A 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback